Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Cronus Ink Distribution Deal for UK, Ireland

NEW YORK (GenomeWeb News) – Cronus Technologies and Axela today announced a distribution deal to market Axela's instruments in the UK and Ireland.

Cronus will manage the sales and support of Axela's flow-through systems in both countries under the terms of the deal. The systems include the fully automated Ziplex Research System for gene and protein microarray analysis, and the dotLab mX System for real-time, multiplex immunoassays. Cronus will also market Axela's panelPlus Technology for creating custom multiplex panels for flow-through biomarker analysis.

"The Ziplex and dotLab mX product range adds another string to our biomarker discovery and validation portfolio and allows us to truly collaborate with our customers in a meaningful and strategic way," Kevin Fairman, CEO of Cronus, said in a statement. "This positive addition combined with a great working relationship with the Axela team will allow our customers to push the boundaries and time constraints in biomarker research."

The companies did not reveal the terms of the deal, which follows an agreement Toronto-based Axela inked with Digilab in August to distribute Axela's products in the US.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.